New approaches to the immunotherapy of cancer

References

• OETTGEN HP, OLD LJ: The history of cancer itrununo-therapy. In: The Biologic Therapy of Cancer, DeVita VT, Hellman S, Rosenberg SA (Eds) Lippincott, Philadelphia, 1991 p87–119.
   Google Scholar
• LANDSTEINER K, CHASE MW: Experiments on transferof cutaneous sensitivity to simple compounds. Proc . Soc. Exp. Bio. Med. (1942) 49: 688.
   Google Scholar
• COLEY WB: Treatment of inoperable rnAignant tu-mours with the toxins of erysipelas and the Bacillus prodigosus. Trans. Amer. Surg. Assoc (1894)12:183.
   Google Scholar
• MORTON DL, HUNT KK, BAUER RI, LEE JD: Immuno-therapy by active immunization of the host using non-specific agents. In: The Biologic Therapy of Cancer, DeVita VT, Hellman S, Rosenberg SA (Eds) Lippincott, Philadelphia, 1991 p627–650.
   Google Scholar
• ROSENBERG SA, LOTZE MT, MOOL LM, ETAL.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and in-terleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med. (1987) 316:889–897.
   Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, ET AL.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals Surg. (1989) 210(4):474–485.
   Google Scholar
• WEISS GR, MARGOLIN MA, ARONSON FR, ETAL.: A ran-domized phase II trial of continuous infusion inter-leukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. Oncol. (1991) 10:275–281.
   Google Scholar
• PALMER PA, VINKE J, EVE1tS P, ETAL.: Continuous infu-sion of recombinant interleukin-2 with or vvithour autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur.J. Can. (1992) 28A:1028–1044.
   Google Scholar
• STEIN RC, MALKOVOKA V, MORGAN S, ETAL.: The clinical effects of prolonged treatment of patients with ad-vanced cancer with low-dose subcutaneous interleukin-2. Br. J. Can. (1991) 63:275–278.
   Google Scholar
• SLEIJFER D TH, JANSSEN RAJ, BUTER J, ETAL: Phase 11 study of subcutaneous interleukin-2 in unselected pa-tients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. (1992) 10:1119–1123.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, POLIWODA H, KIRCHNER H: Alpha-inter-feron and interleukin-2 in renal cell carcinoma: studies In nonhospitalised patients. Seminars in Oncology (1991) 18:108–112.
   PubMed Web of Science ®Google Scholar
• GHOSH AK, DAZZI H, THATCHER N, MOORE M: Lack ofcorrelation between peripheral blood LAK cell function and clinical response in patients with advanced mela-noma receiving interleukin-2. Int. J. Can. (1989) 43:410–414.
   PubMed Web of Science ®Google Scholar
• PARDOLL D: New strategies for active immunotherapywith genetically engineered cells. CUM. Opin. Immunol (1992) 4:619–623.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, PACKARD BS, AEBERSOLD PM, ETAL: Use ofand IL-2 in the management of malignantmelanoma: a preliminary report. New Engl.J. Med. (1988) 319:1676–1680.
   PubMed Web of Science ®Google Scholar
• EZZEL C: Committee may withhold funds from gene therapy triaL MH (1993) 5(4):32–34.
   Google Scholar
• ABERSOLD P, HYATT C, JOHNSON S, ET AL.: Lysis of autologous melanoma cells by tumor-infiltrating lym-phocytes: association with clinical response. J. Natl. Can. Instit. (1991) 83(13):932–937.
   Google Scholar
• BYSTRYN J-C, ORATZ M, HENN A, ETAL.: Relationship between immune response to melanoma vaccine and clinical outcome in stage 11 malignant melanoma. Can-cer(1992) 69:1157–1164.
   Google Scholar
• MORTON DL, WANEK L, NIZZE JA, ETAL.: Improved long term survival after lymphadenectomy of melanoma metastatic to regional nodes. Annals Surg. (1991) 214(4):491–501.
   Google Scholar
• HANNA M, RANSOM JH, POMATO N, ETAL.: Active specificimmunotherapy of human colorectal carcinoma with an autologous tumour BCG-vaccine. In: Specific Immuno-therapy of Cancer with Vaccines, Brystryn, Ferrone, Living-ston (Eds) Annals Sci. New York Acad.(1993) 690:135–146.
   Google Scholar
• BERD D, MAGUIRE HC, MCCUE P, MASTRANGELO MJ: Treatment of metastatic melanoma with an autologous tumour cell vaccine. J. Clin. Oncol. (1990) 8:1858–1867.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS, HAREL W, KAN-MITCHELL ET AL: Activespecific immunotherapy of human colorectal carci-noma with an autologous tumour BCG-vaccine. In: Spe-cific Immunotherapy of Cancer with Vaccines, Brystryn, Ferrone, Livingston (Eds) Annals Sci. New York Acad.(1993) 690:153–166.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS: Active specific immunotherapy of can-cer: Therapeutic vacccines ("therracines") for the treat-ment of disseminated malignancies. In: Biological Approaches to Cancer Treatment: Biomodulation, Mitchell MS (Ed) McGraw-Hill, New York 1992 p326–351.
   Google Scholar
• HERSEY P: Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. WorldJ. Stag. (1992) 16:251–260.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, BASH JA, LEFTHEMOTIS H, ETAL.: Positive relationship of clinical and serological responses to vaccinia melanoma oncolysate. Arch. Surg. (1987) 122:1460–1463.
   Google Scholar
• LIVINGSTON PO, RITTER O, SRIVASTAVA P, ETAL.: Char-acterization of IgG and IgM antibodies induced in mela-noma patients by immunization with purified GM2 gang,lioside. Can. Res. (1989)49:7045–7050.
   Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P, ETAL.: A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643.
   PubMed Web of Science ®Google Scholar
• DOLTDEVANI A, HULEIHEL M, ZOLLER M, ETAL.: Reducedtumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha gene transfer. Int. J. Can. (1992) 51:822–830.
   Google Scholar
• BUBENIK J, VOITENOK NN, KIELER J: Local administra-tion of cell containing an inserted 11-2 gene and pro-ducing 1L-2 inhibits growth of tumours in nu/nu mice. Immunol. Lett. (1988) 19:279–282.
   PubMed Web of Science ®Google Scholar
• FEARON ER, PARDOLL DM, ITAYA T, ETAL.: IL-2 produc-tion by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell (1990) 60:3539–3543.
   Google Scholar
• GANSBACHER B, ZIER K, DANIELS B, ET1L-2 genetransfer into tumour cells abrogates tutnorigenicity and Induces protective immunity. J. Exp. Med. (1990) 172:1217–1224.
   PubMed Web of Science ®Google Scholar
• CONNOR J, BANNERJI R, SAITO S, ETAL.: Regression ofbladder tumors in mice treated with IL-2 gene-modified tumor cells. J. Exp. Med. (1993) 177: 1127–1134.
   Google Scholar
• KIM TS, RUSSELL SJ, COLLINS M, COHEN E: Immunity to B16 melanoma in mice immunized with 11-2 secret-ing allogeneic fibroblasts expressing melanoma-asso-ciated antigens. Int. J. Can. (1992) 51:283–289.
   PubMed Web of Science ®Google Scholar
• GOLUMBEK P, LAZENBY A, LEVITSKY HI, ET AL.: Treat-ment of established renal cancer by tumor cells engi-neered to secrete 11–4. Science (1991) 254:713–716.
   Google Scholar
• HOCK H, DORSCH M, KUNZENDORF U, ETAL.: Mecha-nisms of rejection induced by tumor cell-targeted gene transfer of 11–2, I1-4, 11–7 tumor necrosis factor or interferon gamma. Proc. Natl. Acad. Sci. USA (1990) 90:2774–2778.
   Google Scholar
• MULE JJ, MCINTOSH JK, JABLONS DM, ROSENBERG SA: Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med. (1990) 171(3):629–636.
   PubMed Web of Science ®Google Scholar
• MULE JJ, CUSTER MC, TRAVIS WD, ROSENBERG SA: Cellu-lar mechanisms of the antitumour activity of recombi-nant 1L-6 in mice. J. Immunol. (1992) 148(83:2622–2629.
   PubMedGoogle Scholar
• PORADOR A, TZEHOVAL E, KATZ A, ET AL.: 11–6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers im- munotherapeutic competence against parental metas-tic cells. Can. Res. (1992) 52:3679–3686.
   Google Scholar
• HOCK H, DORSCH M, D1AMANTSTEIN T, BLANKENSTEIN T: IL-7 induces CD4+ T cell-dependent tumor rejection. J Exp. Med. (1991) 174:1291–1298.
   PubMed Web of Science ®Google Scholar
• JICHA DL, MULE JJ, ROSENBERG SA: Interleukin 7 gener-ates antitumor cytotoxic lymphocytes against murine sarcomas with efficacy in cellular adoptive immuno-therapy. J. Exp. Med. (1991) 174(12):1511–1515.
   PubMedGoogle Scholar
• GANSBACHER B, ZIER K, DANIELS B, ET AL.: Genetic modification of a murine flbrosarcoma to produce IL-7 stimulates host cell infiltration and tumor immunity. Can. Res. (1992) 52:3931–3937.
   Google Scholar
• AOKI T, TASHIRO K, MIYATAKE S, KINASHI T, NAKANOK, ODA Y, ET AL.: Expression of murine interkukin 7 in a murine glioma cell line results in reduced tu-morigenicity in vivo. Proc. Natl. Acad. Sci USA (1992) 89(9):3850–3854.
   Google Scholar
• GANSBACHER B, ZIER K, DANIELS B, ET AL.: Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tu-mor immunity. Cancer Res. (1990) 50:7820–7825.
   Google Scholar
• ASHER AL, MULE JJ, KASID A, ET AL.: Murine tumor cells transduced with the gene for tumor necrosis factor-al-pha. J. Immunol.. (1991) 146:327–3234.
   Google Scholar
• BLANKENSTEIN T, QINZ, UBERLA K, E7' AL.: Tumor sup-pression after tumor cell-targeted tumor necrosis alpha gene transfer. J. Exp. Med. (1991) 173:1047–1052.
   Google Scholar
• COLOMBO MP, FERRARI G, STOPPACCIARO A, ET AL.: Granulocyte colony-stimulating factor gene suppresses tumorogenidty of a murine adenocarcinoma in vivo. I. Exp. Med. (1991) 173:889–897.
   Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A, ET AL.: Vaccination with irradiated tumor cells engineered to secrete mur-ine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumour Immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539–3543.
   Google Scholar
• TEPPER RI, MULE JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene 7ber. (1994) 5:153–164.
   Google Scholar
• DING L, LINSLEY PS, HUANG L, ET AL.: IL-10 inhibitsmacrophage costimulatory activity by selectively inhib-iting the up-regulation of B7 expression. J. Immunol. (1993) 151:1224–1234.
   Google Scholar
• KARP S, FARBER A, SALO J, ET AL.: Cytokine secretion by genetically modified nonitrununogenic murine fi-brosarcoma. Tumor inhibition by IL-2 but not by tumor necrosis factor. J. Immunol. (1993) 150:896–908.
   Google Scholar
• BERGLTI L, SCHENA M, GAIDANO G, ET AL.: IL-3 and IL-6 synergistically promote the proliferation and differen-tiationa of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. (1989) 170:613–618.
   Google Scholar
• BROWNING MJ, BODMER WE: MHC antigens and can-cer:implications for T-cell surveillance. Curr. Opin. Im-munol. (1992) 4:613–618.
   PubMed Web of Science ®Google Scholar
• CORDON-CARDO C, FUKS Z, DROBNJAK M, ET AL.: Ex-pression of 111A-A, B, C antigens on primary and me-tastatic tumor cells populations of human carcinomas. Can. Res. (1991) 51:6372.
   Google Scholar
• NATALI P, NICOTRA M, BIGOTrI A, ET AL.: Selective changes in expression of IILA Class I polmorphic de- terminants in human solid tumors. Proc. Natl. Acad. Sci. USA (1989) 86:6719.
   Google Scholar
• SMITH M, BODMER W, BODMER J: Selective loss of IHA-A,B, C locus products in colorectal adenocarcinoma. Lan-cet (1988)1:823.
   PubMed Web of Science ®Google Scholar
• HUI K, GROSVALD F, FETESTEIN F: Rejection of trans-plantable DR leukaemia cells following MHC DNA-me-diated cells transformation. Nature (1985) 315:301.
   PubMedGoogle Scholar
• WALLICH R, BLTLBUC N, HAMMERING GJ, ET AL.: Abroga-tion of metastatic properties of tumor cells by tie novo expression of II-2K antigens following II-2 gene trans-fection. Nature (1985) 315:301.
   Google Scholar
• TANADA K, HAYASHI H, HAMADA C, ET AL.: Expressionof MHC Class I antigens as a strategy for the potentiation of the immune recognition of tumor cells. Proc. Natl. Acad. Sci. USA (1986) 83:8723.
   Google Scholar
• PORGADOR A, FELDMAN M, EISENBACH L: II-2Kb trans-fection of B16 melanoma cells results in reduced tu-morogenicity and metastatic competence. J. Immunogenet. (1989) 16:291.
   PubMedGoogle Scholar
• PLAKSIN D, GELBER C, FELDMAN M, EISENBACH L: Rever-sal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic II-2 Kb gene. Proc. Natl. Acad. Sci. USA (1988) 85:4463.
   PubMed Web of Science ®Google Scholar
• GELBER C, PLAKSIN D, VADAI E, ET AL.: Abolishment of metastasis formation by murine tumor cells transfected with foreign II-2K genes. Can. Res. (1989) 49:2366.
   Google Scholar
• FERRY N, DUPLESSIS O, HOUSSIN D, ET AL.: Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl. Acad. Sci. USA (1991) 99:8377–8381.
   Google Scholar
• KIM M, HERBERMAN R, GORELIK E: Increased sensitivity to TNI7-mediated cytotoxidty of B16 melanoma cells after H-2Kb gene transfection. J. Immunol. (1993)151(7):3467–3477.
   PubMed Web of Science ®Google Scholar
• MANDELBOIM O, FELDMAN M, EISENBACH L: II-2K dou-ble transfectants of tumor cells as antimetastatic cellu-lar vaccines in heterozygous recipients. J. Immunol. (1992) 148(11):3666–3673.
   PubMed Web of Science ®Google Scholar
• JAMES R, EDWARDS S, HUT K, ET AL.: The effect of class 11 gene transfection on the tumorigenicity of the II-2K negative mouse leukaemia cell line K36.16. Immunol. (1991) 72:213–218.
   Google Scholar
• JAMES R, GROSVELD F: DNA-mediated gene transfer into mammalian cells. In: Techniques in Molecular Biology II, Walker J, Gaastra W (Eds), Groom Helon, Kent, UK 1986 p187–202.
   Google Scholar
• OSTRAND-ROSENBERG S, ROBY C, CLEMENTS V: Abroga-tion of tumorigenicity by MHC Class II antigen expres-sion requires the cytoplasmic domain of the class 11 molecules. J. Immunol. (1991) 147:2419–2422.
   PubMed Web of Science ®Google Scholar
• OSTRAND-ROSENBERG S, ROBY C, CLEMENTS V, COLE G: Tumor-speddfic immunity can be enhanced by trans-fection of tumor cells with syngeneic MHC-Class II genes or allogenek MHC-Class I genes. Int. J. Can. (1991) Suppl. 6:61–68.
   Google Scholar
• OSTRAND-ROSENBERG S, THAKUR A, CLEMENTS V: Rejec-tion of mouse sarcoma cells following transfection of MHC Class 11 genes. J. Immunol. (1990) 114:4068–4071.
   Google Scholar
• TOWNSEND S, ALLISON J: Tumor rejection after direct costimulation of CDS+ T cells by B7-transfected mela-noma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• CHEN L, ASHE S, BRADY WA, ET AL.: Costimulation ofantitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD8 and CT1A-4. Cell (1992) 71:1093–1102.
   Google Scholar
• CHEN L, MCGOWAN P. ASHE S, ET AL.: Tumor immuno-genicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. (1994) 179:523–531.
   Google Scholar
• SHAHINIAN A, PFEFFER K, LEE K, ET AL.: Differential Tcell costimulatory requirements in CD28-defecient mice. Science (1993) 261:609–612.
   Google Scholar
• FREEMENA G, BORRIELLO F, HODES R, ETAL.: Uncoveringof functional alternative CTLA-4 counter-receptor in B-7 deficient mice. Science (1993) 262:907–909.
   Google Scholar
• HATHCOCK K, LASZIO G, DICKLER H, ET AL.: Identifica-tion of an alternative CTLA-4 ligand costitnulatory for T cell activation. Science (1993) 262:905–907.
   Google Scholar
• FREEMAN G, GRIBBEN J, BOUSSIOTIS V, ET AL.: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T-cell proliferation. Science (1993) 262:909–911.
   Google Scholar
• MCARTHUR J, RAULET D: CD28-induced costimulation of T helper type 2 cells mediated by induction of respon-slyness to IL-4.J Exp. Med. (1993) 178:1645–1653.
   PubMed Web of Science ®Google Scholar
• LANDO P, DOHLSTEN M, HEDLUND G, ET AL.: Co-stimu-lation with B7 and targeted superantigen is required for MHC Class 11-Independent proliferation but not cyto-toxicity. Immunol. (1993) 80:236–241.
   Google Scholar
• BOUSSIOTIS V, FREEMAN G, GRAY G, ET AL.: B7 but not intercellular adhesion molecule-1 costirnulation pre-vents the induction of human alloantigen-specific tol-erance.' Exp. Med. (1993) 178:1753–1763.
   Google Scholar
• LUKACS K, LOWRIE D, STOKES R, COLSTON Tumor cells transfected with a bacterial heat-shock gene lose tu-morigenicity and induce protection against tumors. J. Exp. Med. (1993) 178:343–348.
   PubMed Web of Science ®Google Scholar
• TAMURA Y, TS1TBOI N, SATO N, KIKUCHI K: 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's antitumor Immunity. J. Immunol. (1993) 151(10):5516–6624.
   PubMed Web of Science ®Google Scholar
• UDONO H, SRNASTAV P: Heat shock protein 70-associ-ated peptides elicit specific cancer immunity." Exp. Med. (1993) 178:1391–1396.
   PubMed Web of Science ®Google Scholar
• GOLUMBEK P, AZHARI R, JAFFEE E, ET AL.: Controlledrelease, biodegradable cytokine depots: A new ap-proach in cancer vaccine design. Can. Res. (1993) 53:5841–5844.
   Google Scholar
• PLAUTZ GE, YANG Z-Y, WU B-Y, ET AL.: Imrnunotherapyof malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA (1993) 90:4645–4649.
   Web of Science ®Google Scholar
• ZHU N, LIGGITT D, LIU Y, DEBS R: Systemic gene expres-sion after intravenous DNA delivery into adult mice. Science (1993) 261:209–211.
   PubMed Web of Science ®Google Scholar
• CHANG PL, SHEN N, WESTCOTT A: Delivery of recombi-nant gene products with micro-encapsulated cells in vivo. Hum. Gene Ther. (1993) 4:433–440.
   PubMed Web of Science ®Google Scholar
• MANTHORPE M, CORNEFERT-JOHNSON F, HARTIKKA J, ETAL.: Gene therapy by intramuscular injection of plasmid DNA: studies on firefly. luciferase gene expression in mice. Hum. Gene Ther. (1993) 4:419–431.
   PubMed Web of Science ®Google Scholar
• DAVIS H, WHALEN R, DEMENEIX BA:Direct gene transfer Into skeletal muscle in vivo: factors affecting efficiency of transfer and atability of expression. Hum. Gene Ther. (1993) 4:151–159
   Google Scholar
• LYNCH CM, CLOWES M, OSBORNE W, ET AL.: Long-termexpression of human adenosine deaminase in vascular smooth muscle of rats: a model for gene therapy. Proc. Natl. Acad. Sci. USA (1992) 89:1138–1142.
   Google Scholar
• RAOGT T, VINCENT N, CHAFEY P, ET AL.: Efficient ade-novirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature (1993) 361:647–650.
   Google Scholar
• OSANTO S, BROUWENSTYN N, VAESSEN N, ET AL.: Immu-nization with 1L-2 transfected melanoma cell. A phase I-Lt study in patients with metastatic melanoma. Hum. Gene Ther. (1993) 4:323–330.
   Google Scholar
• CHEN Y-T, STOCKERT E, CHEN Y, ET AL.: Identificationof the MAGE-1 gene product by monoclonal and poly-clonal antibodies. Proc. Natl. Acad. Sci. USA (1994) 91:1004–1008.
   Google Scholar
• GAUGLER B, VAN DEN EYNDE B, VAN DER BRUGGEN P, ET AL.: Human gene MAGE-3 codes for an antigen recognised on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. (1994) 179:921–930.
   Google Scholar
• BAICKER A, SCHREURS M, DE BOER A, ET AL.: Melanocyte lineage-specific antigen gp100 is recognised by mela-noma-derived tumor-infiltrating lymphocytes. J. Exp. Med. (1994) 179:1005–1009.
   Google Scholar
• WEIDMANN E, ELDER E, TRUCO M, ET AL.: Usage of TCR Vbeta chain genes in fresh and cultured Tlls from human melanoma. Int. J. Can. (1993) 54:383–390.
   Google Scholar
• SENSI M, SALVI S, CASTELLI C, ET AL.: TCR structure of autologous melanoma-reactive CTL clones: Tumor-in-filtrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2 restricted and melanocyte-lineage-specific CTL done. J. Exp. Med. (1993) 178:1231–1246.
   Google Scholar
• PANDOLFI F, BOYLE IA, TRENTIN L, ET AL.: T cell receptor rearrangements and cytotoxic activities of dones iso-lated from tumor-infiltrating lymphocytes from mela-noma patients. Clin. Exp. Immunol. (1994) 95:141–147.
   Google Scholar
• MACKENSEN A, FERRADINI L, CARCELAIN G, ET AL.: Evi-dence for in situ amplification of Cris with antitumour activity in a human regressive melanoma. Can. Res. (1993) 53:3569–3573.
   Google Scholar
• TAYLOR-PAPADIMITRIOU J, STEWART L, BURCHELL J, BEVERLY P: The polymorphic mudn as a target for inununotherapy. In: Specific Immunotherapy of Cancer with Vaccines, Bystryn J-C, Ferrone 5, Livingston P (Eds), Annals IVY Acad Sci. (1993) 690:69–79.
   Google Scholar
• LONGENECKER M, MCCLEAN G: Prospects for mudn epitopes in cancer vaccines. The Immunologist (1994) 1(3).
   Google Scholar
• JEROME K, DOMENECH N, FINN O: Tumor-specific cyto-toxic T cell clones from patients with breast and pan-creatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mudn complementary DNA. J. Immunol. (1993) 151(3):1634–1662.
   Google Scholar
• TAO M-H, LEVY R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as vaccine for B-cell lymphoma. Nature (1993) 362:755–758.
   PubMed Web of Science ®Google Scholar
• GUO Y, WU M, CHEN H, ET AL.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science (1994) 263:518520.
   Google Scholar
• CHEN ZJ, YANG H, LIU C, ETAL.: Modulation by adjuvants and carriers of the inununogenicity in xenogeneic hosts of mouse anti-idiotype monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen. Can. Res. (1993) 53:112–119.
   Google Scholar
• CHATTOPADHYAY P, STARKEY J, MORROW W, RAY-CHAUDHURI S: Murine monoclonal anti-idiotype anti-body breaks unresponsiveness and induce a specific antibody response to human melanoma-associated proteoglycan in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA (1992) 89:2684–2688.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, NADADA T, PUISIEUX I: Inhibition of human colon cancer growth by antibody-directed hu-man LAK cells in SCID mice. Science (1993) 259:1460–1463.
   PubMed Web of Science ®Google Scholar
• PEACE D, SMITH JW, CHEN W, ET AL.: Lysis of ms oncogene-transformed cells by specific cytotoxk T lym-phocytes elicited by primary in vitro immunization with mutatedras peptide. J. Exp. Med. (1994) 179:473–479.
   Google Scholar
• VILE R, HART I Use of tissue-specific expression of the Herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Can. Res. (1993) 53:3860–3864.
   PubMed Web of Science ®Google Scholar
• LI BI W, PARYSEK L, WARNICK R, STAMBROOK P: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. (1993) 4:725–731.
   PubMed Web of Science ®Google Scholar
• OLDFIELD EH, RAM Z, CULVER 11W, ET AL.: Gene therapy for the treatment of brain tumours using the intra-tu-moral transduction with the thymidine kinase gene and intravenous gandclovir. Hum. Gene Ther. (1993) 4:36–69.
   Google Scholar
• PARDOLL D: New strategies for active immunotherapy with genetically engineered tumor cells. Cum. Opin. Immunol. (1992) 4:619–623.
   PubMed Web of Science ®Google Scholar
• COLOMBO M, FORNI G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today (1994) 15(2)48.
   Google Scholar
• MULLIGAN R: The basic science of gene therapy. Science (1993) 260:926–932.
   PubMed Web of Science ®Google Scholar
• EISENTHAL A, CAMERON RB, UPPENKAMP I, ROSENBERG SA: Effect of combined therapy with LAX cells, I1-2 and specific monoclonal antibodies on established B16 melanoma lung metastases. Can. Res. (1988) 48:7140–7145.
   PubMed Web of Science ®Google Scholar
• TRIOZZI PL, MARTIN EW, GOCHNOUR D, ALDRICH W: Phase lb trial of a synthetic beta human chorionic gonadotropin vaccine in patients with metastatic can-cer. In: Specific Immunotherapy of Cancer with Vaccines, Bystryn J-C, Perrone S, Livingston P (Eds.) Annals NY Acad Sci (1993) 690.
   Google Scholar
• BEUN G, VAN DE VELDE C, FLEUREN G: T-cell based cancer kurnunotherapr direct or redirected tumor cell recognition? Immunology Today (1994) 15(1):11–15.
   PubMedGoogle Scholar